Estimated reading time: 0 minutes, 33 seconds

Merck Handed First Loss in Fosamax Bellweather Trials

The Merck Pharmacy in New York City 1897

A jury in New York City federal court has ruled that pharmaceutical giant Merck didn’t properly warn users about the risks associated with its osteoporosis drug Fosamax, according to a recent article from Reuters.

In the case, a woman who claims she suffered serious jaw injuries from the drug was awarded $285,000.

The case is the first of the Fosamax “bellwether” trials—test cases the legal community uses to gauge the outcome of similar lawsuits—to result in a loss for Merck. The pharmaceuticals behemoth has thus far won five such bellwether trials. There are approximately 4,000 legal claims against Merck for Fosamax-related injuries.

Read the full article from Reuters here.

Enhanced by Zemanta
Read 4180 times
Rate this item
(0 votes)

Visit other PMG Sites:

PMG360 is committed to protecting the privacy of the personal data we collect from our subscribers/agents/customers/exhibitors and sponsors. On May 25th, the European's GDPR policy will be enforced. Nothing is changing about your current settings or how your information is processed, however, we have made a few changes. We have updated our Privacy Policy and Cookie Policy to make it easier for you to understand what information we collect, how and why we collect it.